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Abstract
Macrophages are capable of assuming numerous phenotypes in order to adapt to endogenous and exogenous challenges
but many of the factors that regulate this process are still unknown. We report that Ca
2+/calmodulin-dependent kinase
kinase a (CaMKKa) is expressed in human monocytic cells and demonstrate that its inhibition blocks type-II monocytic cell
activation and promotes classical activation. Affinity chromatography with paramagnetic beads isolated an approximately
50 kDa protein from nuclear lysates of U937 human monocytic cells activated with phorbol-12-myristate-13-acetate (PMA).
This protein was identified as CaMKKa by mass spectrometry and Western analysis. The function of CaMKKa in monocyte
activation was examined using the CaMKKa inhibitors (STO-609 and forskolin) and siRNA knockdown. Inhibition of CaMKKa,
enhanced PMA-dependent CD86 expression and reduced CD11b expression. In addition, inhibition was associated with
decreased translocation of CaMKKa to the nucleus. Finally, to further examine monocyte activation profiles, TNFa and IL-10
secretion were studied. CaMKKa inhibition attenuated PMA-dependent IL-10 production and enhanced TNFa production
indicating a shift from type-II to classical monocyte activation. Taken together, these findings indicate an important new
role for CaMKKa in the differentiation of monocytic cells.
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Introduction
Macrophages are capable of assuming numerous phenotypes
depending on their microenvironment. Three broad categories of
macrophage activation are-classical, type-II (innate) and alterna-
tive. Classical activation of macrophages results from exposure to
IFNc followed by TNFa stimulation [1–3]. Classically activated
macrophages increase their surface expression of CD86 [3,4] and
produce TNFa, IL-12, oxide radicals, and chemokines [3,5,6].
The ligation of the Fc receptors for IgG along with stimulation of
Toll-like receptors, CD40, or CD44 results in type-II activation of
macrophages [3,7]. Type-II activated macrophages show en-
hanced expression of CD86 [3] and generate the cytokines TNFa,
IL-1, and IL-6 [7]. These macrophages, however, also elaborate
IL-10, which differentiates them from classically activated
macrophages [7,8]. The third type of activation, alternative
activation, fails to up-regulate CD86 [3,9] but does enhance
macrophage production of arginase [10], IL-1 receptor antagonist
[11] and IL-10 [9]. Interestingly, the activation of this pathway
results in macrophages with a reduced ability to kill microbes [12] .
Therefore, classical activation appears to initiate the inflammatory
process through production of the pro-inflammatory cytokines
TNFa, IL-1 and IL-6. Type-II activation likely modulates and/or
reduces inflammation by inducing Th2 helper T-cells [7,8,13]
while increasing synthesis of the anti-inflammatory cytokine IL-10.
Alternative activation directs macrophages to a repair phenotype
[14–16].
Phorbol-12-myristate-13-acetate (PMA)-induced macrophage
activation leads to increased expression of CD86 [17] indicating
a classical or type-II activation phenotype. Importantly, studies
employing PMA and calcium ionophores have linked IFNc-
dependent macrophage activation to pathways requiring both
protein kinase C (PKC) and intracellular Ca
2+ elevation [18–29].
Increased intracellular Ca
2+ following PMA stimulation [27,28] is
important as both a co-factor for the conventional PKC isoforms
activated by PMA [30] and the activation of the Ca
2+/calmodulin
(Ca
2+/CaM) pathway through binding to CaM [31]. CaM
interacts with a wide array of kinases and phosphatases [32],
most notably the Ca
2+/calmodulin-dependent kinase (CaMK)
cascade. Interestingly, Ca
2+/CaM interaction with both CaMKs
and the upstream kinase CaMK kinase (CaMKK) is required for
activation of this pathway [33–36]. In addition to having a CaM
binding domain (CBD) in common, each member of the CaMK
cascade has a catalytic domain adjacent to a regulatory region
containing an autoinhibitory domain (AID) and the CBD [31].
Binding of Ca
2+/CaM to the CBD results in a conformation
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question [31].
Two isoforms of CaMKK have been identified, CaMKKa and
CaMKKb [13,37], both of which have been found in the
cytoplasm [38] and cell nucleus [31,39,40]. Prospective sequence
analysis demonstrates that CaMKKa has a nuclear localization
sequence (a.a. 456–474). The mechanics, however, behind
subcellular localization of the CaMKKs in monocytic cells has
not been previously investigated. CaMKKa has been shown to
phosphorylate CaMKI and CaMKIV [37], mediate Ca
2+-
dependent protection from apoptosis during serum withdrawal
through phosphorylation and activation of Akt [41,42] and
directly interact with serum and glucocorticoid-inducible kinase
1 (SGK1) [41]. As a result of the activation of CaMKIV,
CaMKKa indirectly leads to the activation of ERK-2, JNK-1 and
p38 [31,43,44]. In addition, CaMKKa can cross-talk with the
adenylate cyclase/cAMP pathway [45–47]. In fact, this is one
method for inhibiting CaMKKa activity, where treatment with
forskolin, an adenylate cyclase activator, results in PKA activation
and subsequent phosphorylation of CaMKKa on serine 458,
within the CBD, and threonine 108, potentially involved in
autoinhibition of CaMKKa [46,47]. In addition, a direct means of
CaMKKa inhibition was developed by Tokumitsu et al. with the
generation of STO-609 [48]. STO-609 is an extensively studied
selective inhibitor of CaMKKs, with little effect on PKCs in vitro
and in vivo [48,49]. Finally, little is known of CaMKK’s biologic
role outside of the central nervous system. We have previously
demonstrated that PKCd translocation to the nucleus is associated
with monocyte activation so we investigated the nuclear lysates of
PMA activated U937 cells for proteins absent from nuclear lysates
of non-PMA stimulated monocytes [17]. Here we demonstrate
that human monocytic cells express CaMKKa, that expression of
CD86, CD11b, TNFa, and IL-10 is regulated by CaMKKa and
that inhibition of CaMKKa nuclear translocation is associated
with blocking type-II monocytic cell activation and promoting
classical activation.
Results
PMA induces CaMKKa nuclear localization
Phorbol esters are potent stimulators of monocyte activation
and have been used extensively to study macrophage differenti-
ation [17–23,26–29,50]. In order to examine protein expression
differences between nuclear lysates from PMA treated and non-
PMA U937 cells, paramagnetic bead-assisted affinity chromatog-
raphy was performed. Figure 1A shows that, when U937 cells were
treated with PMA for 48 h, nuclear lysates from these cells
contained an approximately 50 kDa protein that could be affinity
isolated. Nuclear lysates from non-PMA treated cells did not
contain this distinct band. To initiate identification of this protein,
the ,50 kDa silver stained band identified in Figure 1A was
excised from the gel, trypsin-digested and mass mapped by
MALDI-MS. Fragment analysis tentatively identified this protein
as CaMKKa (GenBank accession number AF099105). Confirma-
tion of this identification was performed by Western analysis using
an anti-CaMKKa antibody (Figure 1B). Western analysis
demonstrated that CaMKKa was recovered by affinity chroma-
tography of nuclear lysates from PMA-treated cells while only
traces were detected from nuclear lysates from non-PMA treated
cells. Finally, Figure 1C demonstrates that CaMKKa was present
in whole cell lysates of both PMA treated and untreated U937
cells. In addition, CaMKKb was not detected (data not shown).
Taken together, these results confirm that CaMKKa is present in
monocytic cells and indicates that it localizes to the nucleus of
PMA stimulated cells.
Inhibition of PKC decreases PMA-dependent up-
regulation of CD86/CD11b expression
To determine the role of PKC in the PMA-induced CD86/
CD11b expression, bisindolylmaleimide inhibition studies were
performed. Figure 2A–B show that when U937 cells were
pretreated with bisindolylmaleimide for 15 min prior to PMA
stimulation for 48 h cell surface CD86/11b expression was
inhibited by more than 75% when compared to PMA treatment
alone (P,0.05). This finding indicates that PKC plays a critical
role in modulating PMA-induced activation of costimulatory
markers.
The CaMKKa inhibitor STO-609 enhances PMA-
dependent up-regulation of CD86 but blocks CD11b
expression and CaMKKa nuclear localization
To determine the role of CaMKKa in PMA-dependent
monocytic cell activation, STO-609 inhibition studies were
performed. Figure 3A shows that, when U937 cells were pre-
treated with STO-609 for 6 h prior to PMA addition for 48 h, cell
surface CD86 expression was increased nearly 77% over PMA
Figure 1. PMA induces CaMKKa nuclear localization. (A) U937
cells were treated with (+) or without (2) 100 nM PMA for 48 h and
nuclear lysates were incubated with paramagnetic beads were as the
solid phase. After extensive washing, proteins were resolved and
visualized by SDS-PAGE and silver staining. Results are representative of
three independent experiments. (B) U937 cells were treated and nuclear
lysate affinity chromatography was performed as in panel A. CaMKKa
mass was quantified by Western analysis. Results are representative of
three independent experiments. (C) U937 cells were treated as in panel
A. Affinity chromatography of whole cell lysates was performed as
indicated. CaMKKa mass was quantified by Western analysis. Results are
representative of three independent experiments.
doi:10.1371/journal.pone.0001606.g001
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dependent CD11b cell surface expression by 50% (P,0.05)
(Figure 3B). Next, the consequence of STO-609 on PMA-
dependent CaMKKa nuclear localization was examined. Western
analysis (Figure 3C) demonstrated that STO-609 reduced
CaMKKa nuclear localization by 50% (P,0.05). Similar to
Figure 1C, PMA and/or STO-609 treatment had no impact on
whole cell recovered CaMKKa (data not shown). Importantly, we
have shown that ERK1/2 activation regulates CD86 and CD11b
expression [17]. Interestingly, inhibition of CaMKKa with STO-
609 had no impact on PMA-dependent activation of ERK1/2
(Figure 3D). These findings indicate that STO-609 inhibited
PMA-induced up-regulation of CD11b and augmented PMA-
stimulated CD86 expression. STO-609 also appears to inhibit
PMA-dependent CaMKKa nuclear localization.
Forskolin enhances PMA-dependent CD86 expression
while inhibiting CD11b up-regulation and CaMKKa
nuclear localization
Activation of adenylate cyclase leads to PKA-dependent
phosphorylation and inhibition of CaMKKa [46,47]. To deter-
mine the impact of PKA-mediated inhibition of CaMKKa on
PMA-dependent up-regulation of CD86 and CD11b, activation
studies were performed with the potent adenylate cyclase
activator, forskolin [45]. Figure 4A shows that, when U937 cells
were pre-treated with forskolin for 1 h prior to PMA addition for
48 h, cell surface CD86 expression was increased 130% over PMA
treatment alone (P,0.05). Conversely, forskolin decreased PMA-
dependent CD11b cell surface expression by 50% (P,0.05)
(Figure 4B). PMA-dependent nuclear localization of CaMKKa
was examined by Western analysis (Figure 4C) and was reduced by
60% after forskolin pretreatment (P,0.05). Similar to Figure 1C,
PMA and/or forskolin treatment had no impact on whole cell
recovered CaMKKa (data not shown). Figure 4D demonstrates
that forskolin like STO-609 (Figure 3D) had no impact on ERK1/
2 phosphorylation or mass. These findings indicate that forskolin
inhibits PMA-induced up-regulation of CD11b and augments
PMA-stimulated CD86 expression. Forskolin, also appeared to
inhibit PMA-dependent CaMKKa nuclear localization.
Inhibition of CaMKKa by siRNA enhances PMA-
dependent up-regulation of CD86 but decreases CD11b
expression
Inhibition of CaMKKa with siRNA followed by treatment with
PMA, enhanced CD86 expression by 17% (P,0.05) compared to
PMA alone (Figure 5A) while PMA-induced CD11b expression was
reduced by 24% (P,0.05) compared to PMA alone (Figure 5B).
CaMKKa knockdown did not significantly affect PMA independent
CD86 expression or CD11b. The siRNA scrambled control
sequence did not significantly alter CD86 or CD11b expression in
any of the conditions tested. Figure 5C indicates that CaMKKa
expression was decreased by nearly 76% by treatment with
Figure 2. The PKC inhibitor Bisindolylmaleimide inhibits PMA-dependent upregulation of CD86/CD11b expression. (A & B) U937 cells
were pretreated with or without 1 mM bisindolylmaleimide for 15 min prior to activation with 100 nM PMA for 48 h, as indicated. Surface expression
of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated CD86 antibodies. Results significantly
different from PMA at a=0.05 are indicated by (*). Results represent an average of three independent experiments6SEM.
doi:10.1371/journal.pone.0001606.g002
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not significantly affect CaMKKa expression. Taken together, these
data indicate that knockdown of CaMKKa expression alters PMA-
induced macrophage differentiation.
CaMKKa inhibition enhances PMA-induced production of
TNFa while reducing that of IL-10
Type-II activated macrophages produce both TNFa and IL-10
while classically activated macrophages generate just TNFa [3]. To
determine if CaMKKa inhibition was important to macrophage
cytokine production, cytokine assays were performed. Figure 6A
demonstrates that PMA induced an increase in U937 cell TNFa
production from 0 pg/ml to 764622 pg/ml. STO-609 pre-
treatment enhanced this response by 97% (P,0.05) while having
no impact on basal TNFa production. U937 cell IL-10 elaboration
was also increased by PMA from 0 pg/ml to 160640 pg/ml
(Figure 6B). In contrast to TNFa, STO-609 pre-treatment reduced
IL-10 production by 70% (P,0.05). Production of the inflammatory
cytokines IFN-c and IL-2 or the anti-inflammatory cytokines IL-5
and IL-4 were not detected (data not shown). Taken together, these
data show that inhibition of CaMKKa reduces the production of IL-
10 while enhancing that of TNFa indicating a shift from type-II to
classical monocyte activation.
Figure 3. The CaMKKa inhibitor STO-609 enhances PMA-dependent up-regulation of CD86 but blocks CD11b expression and
CaMKKa nuclear localization. (A and B) U937 cells were pretreated with or without 5 mg/ml STO-609 for 6 h prior to activation with 100 nM PMA
for 48 h, as indicated. Surface expression of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated
CD86 antibodies. Results significantly different from PMA at a=0.05 are indicated by (*). Results represent an average of three independent
experiments6SEM. (C) Cells were treated as in panel A and CaMKKa was quantified by Western analysis of nuclear lysates. Results are representative
of three independent experiments. (D) U937 cells were treated as in panel A and ERK1/2 phosphorylation (ERK-p) and mass (ERK) were measured by
Western analysis in whole cell lysates. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0001606.g003
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The co-stimulatory molecule, CD86, is expressed on both
classical and type-II activated macrophages and is necessary to
define a classically activated macrophage [3]. We [17] and others
[51] have previously shown that during monocytic cell activation
CD86 up-regulation requires ERK1/2. Up-regulation, however,
of CD86 during type-II activation has not been thoroughly
studied. Figure 1A shows that a prominent ,50 kDa band was
affinity purified from nuclear lysates derived from PMA-activated
U937 cells. Combining MALDI-MS fragment analysis with
subsequent Western analysis using a CaMKKa specific antibody,
a component of this band was identified as CaMKKa (Figure 1B).
Next, CaMKKa was isolated from whole cell lysates of both PMA
treated and untreated U937 cells. Importantly, PMA did not
increase CaMKKa mass in whole cells (Figure 1C) or nuclear
lysates from non-PMA treated cells (Figure 1B). Taken together,
these data indicate that PMA-dependent activation of monocytic
cells is associated CaMKKa nuclear translocation. Importantly,
the identification of this enzyme in the U937 cell line may provide
Figure 4. Forskolin enhances PMA-dependent CD86 expression while inhibiting CD11b up-regulation and CaMKKa nuclear
localization. (A and B) U937 cells were pretreated with or without 30 mM forskolin for 1 h prior to activation with 100 nM PMA for 48 h, as indicated.
Surface expression of CD11b and CD86 was quantified by flow cytometry using FITC-conjugated CD11b and PE-conjugated CD86 antibodies. Results
significantly different from PMA at a=0.05 are indicated by (*). Results represent an average of three independent experiments6SEM. (C) Cells were
treated as in panel A and CaMKKa was quantified by Western analysis of nuclear lysates. Results are representative of three independent experiments.
(D) U937 cells were treated as in panel A and ERK1/2 phosphorylation (ERK-p) and mass (ERK) were measured by Western analysis in whole cell
lysates. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0001606.g004
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the potential of CaMKKs as therapeutic targets is currently being
investigated by our laboratory.
Given the central role of monocytes in the immune response
and the importance of coordinating activation in specialized
microenvironments [52] we investigated the effect of PMA
stimulation on CD86/CD11b expression. We have previously
shown that PKCd plays a critical role in IL-4 mediated PMA-
induced CD86/CD11b expression [17], however, prolonged
exposure to PMA has been shown to down-regulate certain PKCs
[53] so we preformed experiments to investigate the effects of PKC
inhibition. Treatment with bisindolylmaleimide significantly
attenuated PMA-induced CD86 and CD11b expression
(Figure 2A–B) indicating that activation of PKCs was essential to
PMA-induced CD86 and CD11b expression. Next, in order to
determine if CaMKKa regulated CD86 expression, CD86
expression was examined in PMA-activated U937 cells. Inhibition
of CaMKKa with STO-609 [48] increased PMA-dependent
CD86 expression nearly 77% while PMA-induced CD11b
expression was attenuated by 50% (Figures 3A–B). STO-609 also
impaired the translocation of CaMKKa into the nucleus following
PMA-activation (Figure 3C). This is consistent with the hypothesis
that activation of CaMKKa may lead to nuclear targeting of this
protein and initiation of downstream events [38–40]. ERK1/2 is
Figure 5. Inhibition of CaMKKa by siRNA enhances PMA-dependent up-regulation of CD86 but decreases CD11b expression. (A and
B) Cells were treated with 0.25 mg of either CaMKKa siRNA or scramble siRNA control prior to stimulation with 100 nM PMA for 48 h. Surface
expression of CD11b and CD86 was quantified by flow cytometry. Results significantly different from PMA at a=0.05 are indicated by (*). Results
represent an average of three independent experiments6SEM. (C) Cells were treated as in A and CaMKKa protein expression was quantified by
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We have shown that CD86/CD11b expression after activation
requires ERK1/2 [17]. Notably, CaMKKa can lead to the
activation of ERK-2 [44]. To determine if CaMMKa regulated
ERK1/2, STO-609 inhibition of CaMMKa was utilized. As
Figure 3D shows, PMA-dependent ERK1/2 activation was not
enhanced or decreased by STO-609. While the PKC and Ca
2+/
CaM pathways can interact [30,54–56], our data may represent
that under strong MAPK stimulation, via PMA-PKC, the
phosphorylation of ERK by CaMK is redundant and consequent-
ly inhibition of CaMKK is without effect.
Work by Wayman et al. and Matsushita et al. demonstrated that
forskolin inhibits CaMKKa activity by inducing PKA-dependent
[45] phosphorylation of serine 458, within the CaMKKa
calmodulin binding domain, and threonine 108, involved in
autoinhibition of CaMKKa [46,47]. To investigate the impact of a
second mechanism of CaMKKa inhibition on PMA-induced
CD86/CD11b expression, we used forskolin, a potent activator of
adenylate cyclase [45]. Figures 4A–B demonstrates that forskolin,
itself, does not impact CD86 or CD11b expression. This result was
expected because we have shown that PMA dependent-up-
regulation of CD86 requires ERK1/2 activation [17] and
Figure 4D demonstrates that forskolin alone did not activate
ERK1/2. However, when forskolin was used in conjunction with
PMA, a doubling of CD86 expression and an attenuation of
CD11b up-regulation was observed. Additionally, CaMKKa
nuclear translocation was blocked by forskolin (Figure 4C), while
PMA-stimulated ERK-1/2 activation was unaffected (Figure 4D).
These effects mimicked that of STO-609 (Figure 3), an inhibitor of
CaMKKa that works through an entirely different mechanism
[48]. Although the use of two pharmacological inhibitors of
CaMKKa that act through different mechanisms provides strong
evidence that CaMKKa regulates PMA-induced CD86 and
CD11b expression, direct molecular interventions provide the
strongest evidence. When CaMKKa expression was reduced by
siRNA knockdown, PMA-dependent CD86 expression was
enhanced and CD11b expression decreased as expected. Taken
together, these findings indicate that CaMKKa is an important
regulator of macrophage differentiation.
PMA activates both Ca
2+-dependent and -independent events
within the cell. Specific surface proteins on murine macrophages
such as HLA-DR and FccR are increased in response to PMA,
which is dependent on increased Ca
2+, but is not affected by the
Ca
2+/CaM or PKC pathways [19]. Cellular spreading of murine
macrophages in response to PMA requires intracellular Ca
2+ [28],
treatment of malignant myeloid progenitor cells from patients with
chronic myelogenous leukemia with a calcium ionophore leads to
expression of CD86 and other surface markers including those for
dendritic cell-activation and adhesion [57], and expression of
CD86 in human monocyte-derived dendritic cells is also increased
by elevated Ca
2+ flux [58]. However, increased Ca
2+ is not always
the critical factor in PMA-mediated effects. In the case of
macrophage priming, increased intracellular Ca
2+ alone is not
sufficient and stimulation with activators of PKCs, such as PMA, is
needed to achieve priming of these cells [21,22]. Arachadonic acid
release and IgG-mediated phagocytosis following PMA activation
of human monocytes occurs through activating a Ca
2+-indepen-
dent phospholipase A2 [59], potentially mediated by PKC. In
addition, PMA has defined Ca
2+-independent effects in glomerular
mesangial cells [60], T lymphocytes [61], and mouse oocytes [62].
Therefore, we examined the impact of ionomycin, a Ca
2+-
ionophore, on PMA-induced CD86 expression and found no effect
of ionomycin alone or in combination with PMA (data not shown).
This indicates that increased CD86 expression requires more than
Figure 6. CaMKKa inhibition enhances production of TNFa while reducing that of IL-10. (A and B) U937 cells (1610
6 cells/treatment) were
pretreated with or without 5 mg/ml STO-609 for 6 h prior to activation with 100 nM PMA for 48 h, as indicated. TNFa and IL-10 concentrations were
quantified from culture supernatants by cytokine assays. Results significantly different from PMA at a =0.05 are indicated by (*). Results represent an
average of three independent experiments6SEM.
doi:10.1371/journal.pone.0001606.g006
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2+ and activation of the Ca
2+/CaM pathway [63].
We have also shown that inhibition of PMA-dependent activation
of PKCd markedly augments CD86 expression while blocking
CD11b expression in monocytic cells [17]. This effect was
correlated with loss of PKCd activation and failure of PKCd to
translocate to the nucleus. PKCd is classified as a novel isoform in
that it does not require Ca
2+ but is dependent on diacylglycerol and
phosphatidyserine for activity [64]. Therefore, one possibility to
account for CaMKKa nuclear translocation is via an association
with PKCd. Since activation of CaMKKa appears to be important
for nuclear targeting (Figures 3–4) interaction with PKCd could
represent a critical step in this regulatory process, although further
evidence is needed to establish such a relationship.
Finally, an important distinction between classically activated
macrophages and type-II activated macrophages is the type of
cytokines produced. Both forms of activation result in the
production of TNFa, however IL-10 is only elaborated during
type-II activation [3]. IL-10 is a potent anti-inflammatory cytokine
[65,66] and Gerber et al. demonstrated that IL-10 was necessary
for the ability of type-II activated macrophages to rescue mice
from a lethal dose of LPS [7]. Therefore, we examined the
production of these two cytokines following monocytic cell
activation and found that inhibition of CaMKKa caused a 97%
increase in TNFa production and a 70% decrease in IL-10
production (Figures 6A–B). Taken together these results indicate
that PMA induces a type-II activation profile and that CaMKKa
inhibition shifts the activation state to the classical pathway.
Importantly, our data demonstrate a new role for CaMKKa in
macrophage differentiation, and indicate an association between
the inhibition of CaMKKa and its nuclear translocation.
Materials and Methods
Materials
The monocytic cell line U937 was purchased from American
Type Culture Collection (Manassas, VA). SuperSignalH West Pico
chemiluminescent substrate (cat. #34077) was purchased from
Pierce (Rockford, IL). NitroBindH, Pure nitrocellullose membrane
0.45 mm (cat. #EP4HYB0010) was purchased from Osmotics
(Westborough, MA). Fluorescein isothiocyanate (FITC)-conjugat-
ed anti-CD86 (cat. #MHCD8601-4), and R-Phycoerythrin (PE-
R)-conjugated anti-CD11b (cat. #MHCD11b04) were purchased
from Caltag (Burlingame, CA). Anti-phospho-ERK1/2- Thr202/
Tyr204 (cat. #9106) was purchased from Cell Signaling
Technology (Beverly, MA). Anti-CaMKKa(sc-11370) , anti-rabbit
IgG-FITC antibody (sc-2012), CaMKKa siRNA (sc-29904),
Control siRNA (sc-37007) and siRNA transfection reagent (sc-
29528) was purchased from Santa Cruz Biotechnology (Santa
Cruz, California). Anti-ERK1/2 (cat. #06182) was purchased
from Upstate Biotechnology, Inc. (Lake Placid, NY). Forskolin
(cat. #344270), and Bisindolylmaleimide (cat. #203293) were
purchased from Calbiochem (La Jolla, CA). STO-609 (cat.
#1551) was purchased from Tocris Cookson, Inc. (Ellisville,
MO). All other cell culture reagents and chemicals were purchased
from Sigma (Saint Louis, MO).
Cell Culture
U937 cells were cultured in growth media (RPMI 1640
supplemented with 10% fetal bovine serum, 2.0 g/L sodium
bicarbonate, 2.5g/L glucose, 100,000 units/L penicillin, and
100 mg/L streptomycin, 1 mM sodium pyruvate and 10 mM
HEPES, pH 7.4) as previously described [17]. Cells were passaged
1:2 with fresh medium every three days. For all experiments, cells
were washed twice and re-suspended in growth media at 1610
6
cells/ml with the indicated treatments.
CaMKKa Knockdown
siRNA knockdown of CaMKK was performed according to the
manufacturer’s instructions. In brief, cells were cultured in
antibiotic free media for 24 h washed twice and resuspended in
200 ml transfection media containing 0.25 mg of siRNA duplex
(scrambled control or CaMKKa cocktail) and 2 ml of siRNA
transfection reagent. Cells were incubated as described above for
6 h, then 500 ml of fresh transfection media was added and cells
incubated for an additional 24 h. Finally, cells were washed and
resuspended in growth media and treated with PMA for 48 h and
assayed by flow cytometry. CaMKKa expression was quantified
by intracellular flow cytometry.
Nuclear Lysates
were isolated as previously described [17]. 1610
6 cells/test were
stimulated as indicated and then washed with ice-cold DPBS, spun
and resuspended in Buffer A (10 mM KCl, 1.5 mM MgCl2,1m M
dithiothreitol (DTT), 1 mg/ml leupeptin, 1 mg/ml aprotinin,
1 mM PMSF and 10 mM HEPES, pH 7.9). After 15 min on
ice, lysates were passed through a 26K gauge needle three times
and then centrifuged at 8006g for 10 min at 4uC. The nuclear
pellet was re-suspended in Buffer A and layered over a 30%
sucrose cushion (w/v in Buffer A) and centrifuged 15 min at
50006ga t4 uC. The purified nuclear pellet was then incubated in
25% glycerol, 400 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml
aprotinin and 10 mM HEPES, pH 7.9 with vortexing for 30 min
at 4uC. After centrifugation at 16,0006g for 30 min at 4uC, the
supernatant (nuclear extract) was analyzed
Whole cell Lysates
were prepared as previously described [17]. In brief, 1610
6 cells/
test were lysed in 1 ml of ice-cold lysis buffer (1% Triton X-100,
150 mM NaCl, 1 mM NaF, 1 mM EGTA, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 2 mg/ml aprotinin, 2 mg/ml
leupeptin, 1 mM sodium orthovanadate and 50 mM Tris-base,
pH 7.4) by double passage through a 26K-gauge needle. Lysates
were cleared by centrifugation at 16,0006g for 10 min.
Paramagnetic Bead Affinity Chromatography
U937 cell nuclear or whole cell lysates, generated as above
(Cellular Fractionation), were diluted to 1 mg/ml with Buffer A
(without Triton X-100) to ensure adequate column absorption and
flow. Lysates and paramagnetic beads (Miltyni, Auburn, CA) were
then incubated together at 21uC for 5min. Bead complexes were
washed extensively with 10 mM KCl, 7% glycerol, 1 mM DTT,
10 mM HEPES, pH 7.9. Columns were then eluted with 1%
SDS, 1 mM DTT, 10 mM Tris-HCl, pH 6.8, and proteins
separated on 10% polyacrylamide gels. Gels were either electro-
transfered to nitrocellulose for Western analysis or silver stained
using the SilverQuest
TM kit (Invitrogen, Carlsbad, CA). For silver
staining, 15610
6 cells/test were used.
Mass Spectrometry (MS)
Proteins were separated by SDS-PAGE and silver stained using
SilverQuest (Invitrogen) following manufactures instructions.
Silver stained bands were excised, de-stained (following manufac-
tures instructions) and speed vacuum-dried until tacky. Gel pieces
were rehydrated in 100 mM ammonium bicarbonate with 2 mg/
ml trypsin and incubated at 37uC for 36 h. Trypsin digestion was
stopped by addition of 10% trifluoroacetic acid (TCA) and
peptides extracted into 50 ml of 10% TCA/60% acetonitrile.
Samples were then concentrated by 1/3 via speed vacuum drying
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using ZipTip (Millipore) packed with SCX resin (Millipore).
Peptide molecular ions were analyzed in the positive ion mode
using a Voyager 4066 Mass Spectrometer (Applied Biosystems)
where acceleration voltage was set at 20 kV and 100 laser shots
were summed. To calibrate peptide digestion, equine myoglobin
was used as an external standard. PeptIdent (Swiss Institute of
Bioinformatics) was used to identify the monoisotope peptide
masses where 1 missed cleavage was allowed and a minimum of 4
matching peptides was required for a match. The pI range was
62.00 and the molecular weight range was 620%.
Flow Cytometry
was performed as previously described [50]. In brief, after
indicated treatments, cells were incubated in growth media
supplemented with 5 mM EDTA for 1 hr at 37uC and then
washed once in 0.5% Dulbecco’s phosphate-buffered saline
(DPBS) containing 0.5% BSA (DPBS-BSA) without calcium and
magnesium. Fluorochrome-conjugated antibodies at 10 mg/ml/
test were added to 1610
6 cells and incubated on ice for 15 min
and then washed with DPBS-BSA 0.5% Fluorescence was
detected on an Epics XL flow cytometer (Beckman Coulter,
Fullerton, CA) quantifying 1.5610
4 events using gates to exclude
nonviable cells as determined by propidium iodide staining. For
intracellular staining, cells were fixed in 2% formalin/PBS for
10 m at room temperature, washed twice with DPBS-BSA 0.5%
and blocked with PBS containing 10% fetal bovine serum for
20 m. 100 ml of PBS/FBS containing 0.2 % triton and 10 ug/ml/
test of CaMKKa antibody or isotype control was added and cells
were allowed to incubate overnight at 4uC. Cells were then washed
twice with DPBS-BSA 0.5% and blocked with PBS containing
10% fetal bovine serum for 20 m. 100 ml of PBS/FBS containing
0.2 % triton and 10 ug/ml/test anti-IgG-FITC detection antibody
was added cells were allowed to incubate for 1 h at room
temperature then washed twice with DPBS-BSA 0.5%. Fluores-
cence was detected as above. Cell viability for all experiments was
at least 85%. Median values of each population were used to
indicate the levels of expression of each antigen assayed.
Western analysis
was performed as previously described [50]. Proteins were
resolved by SDS-PAGE (1610
6 cells/lane) in 10% gels and then
electro-transferred to nitrocellulose. Immunoreactive proteins
were visualized with the indicated primary antibodies using
enhanced chemiluminescence (ECL) (Amersham) followed by
densitometry.
Cytokine Assays
Measurement of IL-10, IL-4, TNF-a, IL-2, IL-5 and IFN-c were
performed using the Cytometric Bead Array Kit (BD PharMingen)
as per the manufacturer’s instructions. Fluorescence was detected
on a Cytomation MoFlo flow cytometer (DakoCytomation
Colorado Inc, Fort Collins, Colorado) quantifying 5610
4 events.
Absolute cytokine amounts were calculated by comparison to a
standard curve generated using a 3
rd order polynomial regression
curve-fitting algorithm. Limits for detection were IL-10 (2.8 pg/
ml), IL-4 (2.6 pg/ml) TNF-a (2.8 pg/ml), IL-2 (2.6 pg/ml), IL-5
(2.4 pg/ml) and IFN-c (7.1 pg/ml).
Statistical Analysis
Where indicated, experimental data was analyzed by the
Student’s t-test for comparison of medians using Microsoft Excel
(Redmond, WA).
Acknowledgments
We thank Dr. Michael Lasker and Dolores Doane for their review of this
manuscript and Dr. Barbara Pilas and Ben Montez with the Keck
Biotechnology Center Flow Cytometry Facility for their help conducting
flow cytometry experiments.
Author Contributions
Conceived and designed the experiments: GF CG ED MH. Performed the
experiments: CG ED MH JY. Analyzed the data: GF CG ED MH JY.
Contributed reagents/materials/analysis tools: GF. Wrote the paper: GF
CG ED MH KK.
References
1. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW (1983) Recombinant
mouse gamma interferon induces the priming step in macrophage activation for
tumor cell killing. J Immunol 130: 2011–2013.
2. Munoz-Fernandez MA, Fernandez MA, Fresno M (1992) Synergism between
tumor necrosis factor-alpha and interferon-gamma on macrophage activation
for the killing of intracellular Trypanosoma cruzi through a nitric oxide-
dependent mechanism. Eur J Immunol 22: 301–307.
3. Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:
209–212.
4. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ (1994) Comparative
analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp
Med 180: 631–640.
5. Planelles L, Thomas MC, Maranon C, Morell M, Lopez MC (2003) Differential
CD86 and CD40 co-stimulatory molecules and cytokine expression pattern
induced by Trypanosoma cruzi in APCs from resistant or susceptible mice. Clin
Exp Immunol 131: 41–47.
6. Iribarren P, Correa SG, Sodero N, Riera CM (2002) Activation of macrophages
by silicones: phenotype and production of oxidant metabolites. BMC Immunol
3: 6.
7. Gerber JS, Mosser DM (2001) Reversing lipopolysaccharide toxicity by ligating
the macrophage Fc gamma receptors. J Immunol 166: 6861–6868.
8. Anderson CF, Mosser DM (2002) A novel phenotype for an activated
macrophage: the type 2 activated macrophage. J Leukoc Biol 72: 101–106.
9. Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA (2002) Blockade of
B7/CD28 in mixed lymphocyte reaction cultures results in the generation of
alternatively activated macrophages, which suppress T-cell responses. Blood 99:
1465–1473.
10. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, et al. (2001) Cutting edge:
Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol
166: 2173–2177.
11. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, et al. (1999)
Alternative versus classical activation of macrophages. Pathobiology 67:
222–226.
12. Schebesch C, Kodelja V, Muller C, Hakij N, Bisson S, et al. (1997) Alternatively
activated macrophages actively inhibit proliferation of peripheral blood
lymphocytes and CD4+ T cells in vitro. Immunology 92: 478–486.
13. Anderson KA, Means RL, Huang QH, Kemp BE, Goldstein EG, et al. (1998)
Components of a calmodulin-dependent protein kinase cascade. Molecular
cloning, functional characterization and cellular localization of Ca2+/
calmodulin-dependent protein kinase kinase beta. J Biol Chem 273:
31880–31889.
14. Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, et al. (2001)
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2
cytokines in vivo: granulomatous pathology is shaped by the pattern of L-
arginine metabolism. J Immunol 167: 6533–6544.
15. Song E, Ouyang N, Horbelt M, Antus B, Wang M, et al. (2000) Influence of
alternatively and classically activated macrophages on fibrogenic activities of
human fibroblasts. Cell Immunol 204: 19–28.
16. Gratchev A, Guillot P, Hakiy N, Politz O, Orfanos CE, et al. (2001)
Alternatively activated macrophages differentially express fibronectin and its
splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol
53: 386–392.
17. Deszo EL, Brake DK, Kelley KW, Freund GG (2004) IL-4-dependent CD86
expression requires JAK/STAT6 activation and is negatively regulated by
PKCdelta. Cell Signal 16: 271–280.
18. Hamilton TA, Becton DL, Somers SD, Gray PW, Adams DO (1985) Interferon-
gamma modulates protein kinase C activity in murine peritoneal macrophages.
J Biol Chem 260: 1378–1381.
19. Klein JB, Schepers TM, Dean WL, Sonnenfeld G, McLeish KR (1990) Role of
intracellular calcium concentration and protein kinase C activation in IFN-
gamma stimulation of U937 cells. J Immunol 144: 4305–4311.
CaMKKa Regulates CD86
PLoS ONE | www.plosone.org 9 February 2008 | Volume 3 | Issue 2 | e160620. Sebaldt RJ, Prpic V, Hollenbach PW, Adams DO, Uhing RJ (1990) IFN-gamma
potentiates the accumulation of diacylglycerol in murine macrophages.
J Immunol 145: 684–689.
21. Somers SD, Weiel JE, Hamilton TA, Adams DO (1986) Phorbol esters and
calcium ionophore can prime murine peritoneal macrophages for tumor cell
destruction. J Immunol 136: 4199–4205.
22. Celada A, Schreiber RD (1986) Role of protein kinase C and intracellular
calcium mobilization in the induction of macrophage tumoricidal activity by
interferon-gamma. J Immunol 137: 2373–2379.
23. Weiel JE, Adams DO, Hamilton TA (1985) Biochemical models of gamma-
interferon action: altered expression of transferrin receptors on murine
peritoneal macrophages after treatment in vitro with PMA or A23187.
J Immunol 134: 293–298.
24. Hamilton TA, Rigsbee JE, Scott WA, Adams DO (1985) gamma-Interferon
enhances the secretion of arachidonic acid metabolites from murine peritoneal
macrophages stimulated with phorbol diesters. J Immunol 134: 2631–2636.
25. Johnson HM, Torres BA (1985) Mechanism of calcium ionophore A23187-
induced priming of bone marrow-derived macrophages for tumor cell killing:
relationship to priming by interferon. Proc Natl Acad Sci U S A 82: 5959–5962.
26. Rovera G, Santoli D, Damsky C (1979) Human promyelocytic leukemia cells in
culture differentiate into macrophage-like cells when treated with a phorbol
diester. Proc Natl Acad Sci U S A 76: 2779–2783.
27. Smith BM, Kessler FK, Carchman SH, Carchman RA (1982) The role of
calcium in macrophage chemotaxis to the phorbol ester tumor promoter TPA.
Cell Calcium 3: 503–514.
28. Smith BM, Sturm RJ, Carchman RA (1983) Calcium modulation of phorbol
ester-induced alterations in murine macrophage morphology. Cancer Res 43:
3385–3391.
29. Buys SS, Keogh EA, Kaplan J (1984) Fusion of intracellular membrane pools
with cell surfaces of macrophages stimulated by phorbol esters and calcium
ionophores. Cell 38: 569–576.
30. Lin WW, Chen BC (1998) Distinct PKC isoforms mediate the activation of
cPLA2 and adenylyl cyclase by phorbol ester in RAW264.7 macrophages.
Br J Pharmacol 125: 1601–1609.
31. Soderling TR (1999) The Ca-calmodulin-dependent protein kinase cascade.
Trends Biochem Sci 24: 232–236.
32. Chin D, Means AR (2002) Mechanisms for regulation of calmodulin kinase
IIalpha by Ca(2+)/calmodulin and autophosphorylation of threonine 286.
Biochemistry 41: 14001–14009.
33. Tokumitsu H, Soderling TR (1996) Requirements for calcium and calmodulin in
the calmodulin kinase activation cascade. J Biol Chem 271: 5617–5622.
34. Tokumitsu H, Wayman GA, Muramatsu M, Soderling TR (1997) Calcium/
calmodulin-dependent protein kinase kinase: identification of regulatory
domains. Biochemistry 36: 12823–12827.
35. Haribabu B, Hook SS, Selbert MA, Goldstein EG, Tomhave ED, et al. (1995)
Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain
structure and activation by phosphorylation at threonine-177 by calcium-
calmodulin dependent protein kinase I kinase. Embo J 14: 3679–3686.
36. Tokumitsu H, Muramatsu M, Ikura M, Kobayashi R (2000) Regulatory
mechanism of Ca2+/calmodulin-dependent protein kinase kinase. J Biol Chem
275: 20090–20095.
37. Tokumitsu H, Enslen H, Soderling TR (1995) Characterization of a Ca2+/
calmodulin-dependent protein kinase cascade. Molecular cloning and expression
of calcium/calmodulin-dependent protein kinase kinase. J Biol Chem 270:
19320–19324.
38. Sakagami H, Umemiya M, Saito S, Kondo H (2000) Distinct immunohisto-
chemical localization of two isoforms of Ca2+/calmodulin-dependent protein
kinase kinases in the adult rat brain. Eur J Neurosci 12: 89–99.
39. Eto K, Takahashi N, Kimura Y, Masuho Y, Arai K, et al. (1999) Ca(2+)/
Calmodulin-dependent protein kinase cascade in Caenorhabditis elegans.
Implication in transcriptional activation. J Biol Chem 274: 22556–22562.
40. Nakamura Y, Okuno S, Kitani T, Otake K, Sato F, et al. (1996) Distribution of
Ca2+/calmodulin-dependent protein kinase kinase alpha in the rat central
nervous system: an immunohistochemical study. Neurosci Lett 204: 61–64.
41. Yano S, Tokumitsu H, Soderling TR (1998) Calcium promotes cell survival
through CaM-K kinase activation of the protein-kinase-B pathway. Nature 396:
584–587.
42. Chen BC, Wu WT, Ho FM, Lin WW (2002) Inhibition of interleukin-1beta -
induced NF-kappa B activation by calcium/calmodulin-dependent protein
kinase kinase occurs through Akt activation associated with interleukin-1
receptor-associated kinase phosphorylation and uncoupling of MyD88. J Biol
Chem 277: 24169–24179.
43. Sahyoun N, McDonald OB, Farrell F, Lapetina EG (1991) Phosphorylation of a
Ras-related GTP-binding protein, Rap-1b, by a neuronal Ca2+/calmodulin-
dependent protein kinase, CaM kinase Gr. Proc Natl Acad Sci U S A 88:
2643–2647.
44. Enslen H, Tokumitsu H, Stork PJ, Davis RJ, Soderling TR (1996) Regulation of
mitogen-activated protein kinases by a calcium/calmodulin-dependent protein
kinase cascade. Proc Natl Acad Sci U S A 93: 10803–10808.
45. Rousseau G, Haddad PS, Gallo-Payet N, Bouvier M (2001) Ca(2+)-dependent
sensitization of adenylyl cyclase activity. Eur J Pharmacol 422: 53–60.
46. Wayman GA, Tokumitsu H, Soderling TR (1997) Inhibitory cross-talk by cAMP
kinase on the calmodulin-dependent protein kinase cascade. J Biol Chem 272:
16073–16076.
47. Matsushita M, Nairn AC (1999) Inhibition of the Ca2+/calmodulin-dependent
protein kinase I cascade by cAMP-dependent protein kinase. J Biol Chem 274:
10086–10093.
48. Tokumitsu H, Inuzuka H, Ishikawa Y, Ikeda M, Saji I, et al. (2002) STO-609, a
specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J
Biol Chem. pp 277–1581315818. Epub 12002 Feb 15826.
49. Tokumitsu H, Inuzuka H, Ishikawa Y, Kobayashi R (2003) A single amino acid
difference between alpha and beta Ca2+/calmodulin-dependent protein kinase
kinase dictates sensitivity to the specific inhibitor, STO-609. J Biol Chem 278:
10908–10913. Epub 12003 Jan 10922.
50. Deszo EL, Brake DK, Cengel KA, Kelley KW, Freund GG (2001) CD45
negatively regulates monocytic cell differentiation by inhibiting phorbol 12-
myristate 13-acetate-dependent activation and tyrosine phosphorylation of
protein kinase Cdelta. J Biol Chem 276: 10212–10217.
51. Uchi H, Koga T, Urabe K, Moroi Y, Furue M (2003) CX-659S, a diaminouracil
derivative, indirectly inhibits the function of Langerhans cells by blocking the
MEK1/2-Erk1/2 pathway in keratinocytes. J Invest Dermatol 120: 983–989.
52. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages
sequentially change their functional phenotype in response to changes in
microenvironmental influences. J Immunol 175: 342–349.
53. Huang FL, Yoshida Y, Cunha-Melo JR, Beaven MA, Huang KP (1989)
Differential down-regulation of protein kinase C isozymes. J Biol Chem 264:
4238–4243.
54. Fukuda N, Honda M, Hatano M (1989) Role of the calcium-calmodulin system
in the adenylate cyclase activity of vascular smooth muscle. Jpn Circ J 53:
270–277.
55. Malnoe A, Cox JA (1985) Relationship among calmodulin-, forskolin-, and
guanine nucleotide-dependent adenylate cyclase activities in cerebellar mem-
branes: studies by limited proteolysis. J Neurochem 45: 1163–1171.
56. MacNeil S, Lakey T, Tomlinson S (1985) Calmodulin regulation of adenylate
cyclase activity. Cell Calcium 6: 213–216.
57. Engels FH, Koski GK, Bedrosian I, Xu S, Luger S, et al. (1999) Calcium
signaling induces acquisition of dendritic cell characteristics in chronic
myelogenous leukemia myeloid progenitor cells. Proc Natl Acad Sci U S A
96: 10332–10337.
58. Skelton L, Cooper M, Murphy M, Platt A (2003) Human immature monocyte-
derived dendritic cells express the G protein-coupled receptor GPR105
(KIAA0001, P2Y14) and increase intracellular calcium in response to its
agonist, uridine diphosphoglucose. J Immunol 171: 1941–1949.
59. Karimi K, Lennartz MR (1995) Protein kinase C activation precedes
arachidonic acid release during IgG-mediated phagocytosis. J Immunol 155:
5786–5794.
60. Moon SO, Palfrey HC, King AC (1984) Phorbol esters potentiate tyrosine
phosphorylation of epidermal growth factor receptors in A431 membranes by a
calcium-independent mechanism. Proc Natl Acad Sci U S A 81: 2298–2302.
61. Keenan C, Long A, Volkov Y, Kelleher D (1997) Protein kinase C isotypes theta,
delta and eta in human lymphocytes: differential responses to signalling through
the T-cell receptor and phorbol esters. Immunology 90: 557–563.
62. Moses RM, Kline D (1995) Calcium-independent, meiotic spindle-dependent
metaphase-to-interphase transition in phorbol ester-treated mouse eggs. Dev
Biol 171: 111–122.
63. MacNicol M, Schulman H (1992) Cross-talk between protein kinase C and
multifunctional Ca2+/calmodulin-dependent protein kinase. J Biol Chem 267:
12197–12201.
64. Mellor H, Parker PJ (1998) The extended protein kinase C superfamily.
Biochem J 332: 281–292.
65. Opal SM, DePalo VA (2000) Anti-inflammatory cytokines. Chest 117:
1162–1172.
66. Strle K, Zhou JH, Shen WH, Broussard SR, Johnson RW, et al. (2001)
Interleukin-10 in the brain. Crit Rev Immunol 21: 427–449.
CaMKKa Regulates CD86
PLoS ONE | www.plosone.org 10 February 2008 | Volume 3 | Issue 2 | e1606